Three-Year Experience With KRAS, BRAF, and NRAS Mutations in Colon Cancer: A Single-Center Study
Abstract
Aim:
This study aimed to evaluate the molecular mutation profiles of KRAS, BRAF, and NRAS in patients diagnosed with colon adenocarcinoma over the past three years in a single tertiary center, and to assess potential associations between mutation status and clinicopathological parameters such as grade, age, gender, lymph node metastasis, distant metastasis, and tumor size.
Materials and Methods:
A total of 100 patients diagnosed with colon adenocarcinoma between 2017 and 2020 and who underwent molecular testing were included. KRAS, BRAF, and NRAS mutation results, along with clinical and histopathological data, were retrospectively collected and statistically analyzed.
Results:
KRAS mutations were detected in 52% of cases, while NRAS and BRAF mutations were identified in 6% and 5% of patients, respectively. No statistically significant associations were found between KRAS mutation status and any of the clinicopathological variables. NRAS mutations were significantly associated with larger tumor diameter (p<0.05). BRAF-mutant tumors were predominantly located in the right colon (80%, p<0.05).
Conclusion:
Our findings are consistent with previously reported mutation frequencies in the literature. Among the evaluated mutations, only NRAS mutation showed a statistically significant association with tumor size. No other significant prognostic or demographic correlations were observed. These findings contribute to the growing understanding of the molecular landscape in colon cancer and its clinical relevance.
Keywords
References
- 1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91.
- 2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32.
- 3. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059-72.
- 4. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079-99.
- 5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45.
- 6. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.
- 7. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924-30.
- 8. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-9.
- 9. Bruzzi M, Brambilla M, Roca E, Sobrero A, Zagonel V, Lonardi S, et al. Influence of molecular status on recurrence site in patients treated for stage III colon cancer: a post hoc analysis of the PETACC-8 trial. Ann Surg Oncol. 2019;26(11):3561-7.
- 10. Wang J, Shen J, Huang C, Cao M, Shen L. Clinicopathological significance of BRAFV600E mutation in colorectal cancer: an updated meta-analysis. J Cancer. 2019;10(10):2332-41.